Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Keren Baruch
2024 Top-of-Mind Issues for Life Sciences Companies | JD Supra
As we reflect on 2023 and make predictions for 2024, it is remarkable the number of significant events occurring this past year that will be impactful for the activities of the life sciences industry going forward. Although there was no single moment like the passage of the Affordable Care Act in 2010, there are numerous distinct events that will loom large in 2024 and beyond. Please see full publication below for more information. Download PDF
Connecticut Follows In The Footsteps Of Other Jurisdictions Requiring Registration Of Pharmaceutical Representatives
Connecticut is the latest state to join the efforts of jurisdictions such as Oregon, Nevada, Washington D.C., and the City of Chicago, Illinois, in further regulating the activities of pharmaceutical representatives. In June, Governor Ned Lamont signed into law "An Act Protecting Patients and Prohibiting Unnecessary Health Care Costs" (the "Act"), which imposes new registration, reporting, and disclosure requirements on pharmaceutical representatives in the State of Connecticut.
Connecticut Follows in the Footsteps of Other Jurisdictions Requiring Registration of Pharmaceutical Representatives | JD Supra
[co-author: Jeremiah Miah] Connecticut is the latest state to join the efforts of jurisdictions such as Oregon, Nevada, Washington D.C., and the City of Chicago, Illinois, in further regulating the activities of pharmaceutical representatives.
Connecticut Follows in the Footsteps of Other Jurisdictions Requiring Registration of Pharmaceutical Representatives
Connecticut is the latest state to join the efforts of jurisdictions such as Oregon, Nevada, Washington D.C., and the City of Chicago, Illinois, in further regulating the activities of pharmaceutical representatives. In June, Governor Ned Lamont signed into law “An Act Protecting Patients and Prohibiting Unnecessary Health Care Costs” (the “Act”), which imposes new registration, reporting, and disclosure requirements on pharmaceutical representatives in the State of Connecticut.
Grow Your Audience with the Power of LinkedIn Newsletters
One of our favorite tools we offer members on LinkedIn is newsletters — since launching in 2017, we’ve seen more than 365M total newsletter subscriptions on LinkedIn. But the value of LinkedIn newsletters is really about sparking conversations and sharing knowledge with your community. We’re seeing people reading and engaging with newsletters more and more: to learn, explore a topic they’re interested in, and get better at their jobs.
New Tools To Help Your Content Shine
Keren Baruch Keren Baruch Director of Product at LinkedIn, Angel Investor Published Feb 23, 2023 We appreciate the effort you put into creating high-quality content on LinkedIn - whether it’s a hot take post on breaking news, a newsletter that digs into industry trends, or a video recap of an event. To help your content stand out and make it easier for others to discover, we’ve developed several new tools.
New Analytics to Understand Your Audience and Grow on LinkedIn
When it comes to building a content strategy and growing your audience, we frequently hear from our creators how important it is to understand who you’re reaching and how your content is performing. We’re adding more to the creator analytics we launched earlier this year and bringing you deeper insights into your audience, as well as the ability to see your top performing posts.
A Creator’s Secret Tool to Success: LinkedIn Newsletters
As creators determine the best methods for sharing their unique expertise and knowledge, newsletters have grown exponentially as a favorite tool. We’re seeing this firsthand at LinkedIn: With more than 150 million newsletter subscriptions on-platform — a 4x increase year-over-year. And the popularity of newsletters makes sense.
LinkedIn Creator Tips for Starting 2022 on the Right Foot - Blogging Tips & Events for Content Creators Everywhere
January 24, 2022 PHOTO: ADOBE | DESIGN: SHEILA PATEL, BLOGHER Keren Baruch, Product Lead for Creator Strategy at LinkedIn, shares the foolproof ways you can up your creator game on the professional network and beyond. As we dive into 2022, all eyes continue to be on the creator economy. We’ve seen incredible growth in the community and as of September 2021, 123,000 LinkedIn members had “creator” in their job title. That’s a 15% jump from 2020 and over a 40% jump from 2019.
Social Media Today Trendline on Social Media Expert Series: Q&A with Keren Baruch
Note from the editor Over the last few years, LinkedIn engagement has gone through the roof, with the company reporting record levels of on-platform activity - specifically, engagement with posts and updates - for five straight quarters running.
LinkedIn Tips for Creators: How to Leverage Your Influence and Build Engagement - Blogging Tips & Events for Content Creators Everywhere
June 29, 2021 Adobe. Design: Freddy Reyes/BlogHer. Every day, millions of posts, videos, courses, and articles are shared on LinkedIn. This generates tens of thousands of comments every hour—and millions of shares and likes. LinkedIn is the perfect place to network and have high-quality, helpful conversations in a relevant professional context to grow your personal brand.
FDA Update: The Latest on Vaccine Development, Inspections, and Conducting Clinical Trials During Covid-19 | JD Supra
This week, FDA Commissioner Stephen M. Hahn, M.D., along with Dr. Anthony S. Fauci, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, and officials from the Centers for Disease Control and Prevention and U.S. Department of Health and Human Services testified on Capitol Hill on the federal response to COVID-19, including the latest on vaccine development and facility inspections.
FDA Update: The Latest On Vaccine Development, Inspections, And Conducting Clinical Trials During Covid-19
Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice): Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below. Mondaq has a "free to view" business model.
FDA Update: The Latest on Vaccine Development, Inspections, and Conducting Clinical Trials During Covid-19
This week, FDA Commissioner Stephen M. Hahn, M.D., along with Dr. Anthony S. Fauci, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, and officials from the Centers for Disease Control and Prevention and U.S. Department of Health and Human Services testified on Capitol Hill on the federal response to COVID-19, including the latest on vaccine development and facility inspections.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Keren
Contact Keren, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack